High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis

European Journal of Cancer

Volumn 51, Issue 6, 2015, Pages 776-785

  Baricevic, Ivona ^a   He, Xiaotong ^a   Chakrabarty, Bipasha ^b   Oliver, Anthony W ^a   Bailey, Charles ^c   Summers, Jeff ^c   Hampson, Lynne ^a   Hampson, Ian ^a   Gilbert, Duncan C ^d   Renehan, Andrew G ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MAIDSTONE HOSPITAL   (United Kingdom)

^d ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

Anal cancer; Chemo radiotherapy; HPV genotyping; HPV vaccination; Human papilloma virus

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; FLUOROURACIL; MITOMYCIN; PROTEIN P16; WART VIRUS VACCINE;

ADULT; AGED; ANAL SQUAMOUS CELL CARCINOMA; ANUS CARCINOMA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIV TEST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; WART VIRUS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925378476     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.01.058     Document Type: Article

References (37)

1. R.P. van der Zee, O. Richel, H.J. de Vries, and J.M. Prins The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 71 8 2013 401 411
2. M.A. Clark, A. Hartley, and J.I. Geh Cancer of the anal canal Lancet Oncol 5 3 2004 149 157
3. H. De Vuyst, G.M. Clifford, M.C. Nascimento, M.M. Madeleine, and S. Franceschi Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis Int J Cancer 124 7 2009 1626 1636
4. L. Abramowitz, A.C. Jacquard, F. Jaroud, J. Haesebaert, L. Siproudhis, and P. Pradat Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study Int J Cancer 129 2 2011 433 439
5. R.J. Hillman, S.M. Garland, M.P. Gunathilake, M. Stevens, N. Kumaradevan, and C. Lemech Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers Int J Cancer 135 4 2014 996 1001
6. E.J. Crosbie, M.H. Einstein, S. Franceschi, and H.C. Kitchener Human papillomavirus and cervical cancer Lancet 382 9895 2013 889 899
7. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 19 2007 1915 1927
8. J. Dillner, S.K. Kjaer, C.M. Wheeler, K. Sigurdsson, O.E. Iversen, and M. Hernandez-Avila Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial BMJ 341 2010 c3493
9. J. Paavonen, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, and D. Apter Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 9686 2009 301 314
10. N. Van de Velde, M.C. Boily, M. Drolet, E.L. Franco, M.H. Mayrand, and E.V. Kliewer Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis J Natl Cancer Inst 104 22 2012 1712 1723
11. A.G. Renehan, M.P. Saunders, P.F. Schofield, and S.T. O'Dwyer Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer Br J Surg 28 2005 28
12. R. Glynne-Jones, L. Kadalayil, H.M. Meadows, D. Cunningham, L. Samuel, and J.I. Geh Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial Ann Oncol 25 8 2014 1616 1622
13. R. Glynne-Jones, and A. Renehan Current treatment of anal squamous cell carcinoma Hematol Oncol Clin North Am 26 6 2012 1315 1350
14. D.C. Gilbert, and R. Glynne-Jones Intensity-modulated radiotherapy in anal cancer: where do we go from here? Clin Oncol (R Coll Radiol) 25 3 2013 153 154
15. L.F. Xi, L.A. Koutsky, A. Hildesheim, D.A. Galloway, C.M. Wheeler, and R.L. Winer Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18 Cancer Epidemiol Biomarkers Prev 16 1 2007 4 10
16. Z. Qmichou, M. Khyatti, M. Berraho, M.M. Ennaji, L. Benbacer, and C. Nejjari Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women BMC Infect Dis 13 1 2013 378
17. D.C. Gilbert, A. Williams, K. Allan, J. Stokoe, T. Jackson, and S. Linsdall P16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy Radiother Oncol 109 1 2013 146 151
18. K.K. Ang, J. Harris, R. Wheeler, R. Weber, D.I. Rosenthal, and P.F. Nguyen-Tan Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 1 2010 24 35
19. S. Heath, V. Willis, K. Allan, K. Purdie, C. Harwood, and P. Shields Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice Clin Oncol (R Coll Radiol) 24 1 2012 e18 e23
20. D. Rischin, R.J. Young, R. Fisher, S.B. Fox, Q.T. Le, and L.J. Peters Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial J Clin Oncol 28 27 2010 4142 4148
21. M. Vosmik, J. Laco, I. Sirak, M. Beranek, E. Hovorkova, and H. Vosmikova Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix Pathol Oncol Res 20 1 2014 131 137
22. F. Rodel, U. Wieland, I. Fraunholz, J. Kitz, M. Rave-Frank, and H.A. Wolff Human papillomavirus DNA load and p16 expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy Int J Cancer 2014
23. E. Serup-Hansen, D. Linnemann, W. Skovrider-Ruminski, E. Hogdall, P.F. Geertsen, and H. Havsteen Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal J Clin Oncol 32 17 2014 1812 1817
24. H.Y. Yhim, N.R. Lee, E.K. Song, J.Y. Kwak, S.T. Lee, and J.H. Kim The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy Int J Cancer 129 7 2011 1752 1760
25. I.O. Maranga, L. Hampson, A.W. Oliver, X. He, P. Gichangi, and F. Rana HIV infection alters the spectrum of HPV subtypes found in cervical smears and carcinomas from Kenyan Women Open Virol J 7 2013 19 27
26. R.D. James, R. Glynne-Jones, H.M. Meadows, D. Cunningham, A.S. Myint, and M.P. Saunders Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial Lancet Oncol 14 6 2013 516 524
27. D.W. Hosmer, S. Lemeshow, and S. May Applied survival analysis: regression modeling of time to event data 2008 Wiley New York
28. Coviello E, Moran J. 'STCOXGOF': module to produce goodness-of-fit test and plot after a Cox model. < http://fmwww.bc.edu/RePEc/bocode/s >; 2008.
29. J. Doorbar, W. Quint, L. Banks, I.G. Bravo, M. Stoler, and T.R. Broker The biology and life-cycle of human papillomaviruses Vaccine 30 Suppl. 5 2012 F55 F70
30. Z. He, Y. Liu, Y. Sun, L.F. Xi, K. Chen, and Y. Zhao Human papillomavirus genital infections among men, China, 2007-2009 Emerg Infect Dis 19 6 2013 992 995
31. L. Alemany, M. Saunier, I. Alvarado-Cabrero, B. Quiros, J. Salmeron, and H.R. Shin Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide Int J Cancer 2014
32. M. Steinau, E.R. Unger, B.Y. Hernandez, M.T. Goodman, G. Copeland, and C. Hopenhayn Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction J Low Genit Tract Dis 17 4 2013 397 403
33. N. Ouhoummane, M. Steben, F. Coutlee, T. Vuong, P. Forest, and C. Rodier Squamous anal cancer: patient characteristics and HPV type distribution Cancer Epidemiol 37 6 2013 807 812
34. N. Powell, K. Cuschieri, H. Cubie, S. Hibbitts, D. Rosillon, and S.C. De Souza Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK) J Clin Virol 58 3 2013 571 574
35. N. Guimera, B. Lloveras, J. Lindeman, L. Alemany, M. van de Sandt, and M. Alejo The occasional role of low-risk human papilloma viruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study Am J Surg Pathol 37 9 2013 1299 1310
36. J.M. Palefsky, A.R. Giuliano, S. Goldstone, E.D. Moreira Jr., C. Aranda, and H. Jessen HPV vaccine against anal HPV infection and anal intraepithelial neoplasia N Engl J Med 365 17 2011 1576 1585
37. J.L. Lines, L.F. Sempere, T. Broughton, L. Wang, and R. Noelle VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy Cancer Immunol Res 2 6 2014 510 517